Light AI Announces Successful Closure of Over-Allotment Option
Light AI Inc. (formerly known as Mojave Brands Inc.) (CBOE CA: ALGO) is thrilled to share recent developments regarding its over-allotment option, which saw a successful full exercise by the Agents. This step resulted in the purchase of an additional 2,757,000 units, amounting to an impressive gross proceeds of $1,516,350 at a rate of $0.55 per unit.
Overview of the Offering
With the latest sales included, the total number of units issued under the long form prospectus offering now totals 33,635,200, achieving an aggregate gross of $18,499,360. Each unit consists of one common share and one-half of a purchase warrant. Holders of each whole warrant will have the opportunity to acquire additional shares at a price of $0.80 for 18 months following issuance.
Details on the Agents’ Role
The offering was conducted by Ventum Financial Corp., acting as the lead agent and sole bookrunner. They were supported by a collaborative team of agents, including Haywood Securities Inc. and Beacon Securities Limited, who played critical roles in this successful endeavor.
Trading Commences on Cboe Canada
In another exciting development, Light AI has received final approval from Cboe Canada Inc. to commence trading of its shares under the symbol “ALGO.” This marks an important milestone, as trading has officially begun, promising to enhance investor access to the company’s innovative offerings.
Company Focus and Technology Overview
Light AI Inc. specializes in the development of cutting-edge artificial intelligence health diagnostic applications. The company is pioneering a smartphone-based technology platform that intends to revolutionize diagnostics by utilizing visual data to identify diseases within seconds. Currently, the platform focuses on images related to StrepA, demonstrating how advanced technology can be integrated into everyday devices.
The AI algorithm has undergone rigorous pre-FDA validation studies, showcasing an impressive accuracy rate of 96.57% in distinguishing between viral and bacterial pharyngitis, particularly for Group A Streptococcus (GAS). Notably, the algorithm has achieved a 100% Negative Predictive Value (NPV), offering a highly reliable method for confirming the absence of Streptococcus A infections.
Global Impact and Future Directions
Globally, viral and GAS pharyngitis afflict over 600 million individuals each year. If untreated, GAS pharyngitis can lead to severe complications, like Rheumatic Heart Disease, creating a global economic burden of over $1 trillion annually. Consequently, Light AI's diagnostic advancements could significantly alleviate the incidence of such complications, thereby reducing the related economic impact.
The technology developed by Light AI is not limited to throat conditions; it has substantial potential for expansion into other medical areas, including analyses of the human eye and skin conditions. The overarching vision is to merge smartphones with AI to form a Digital Clinical Lab, aimed at delivering quick and accessible diagnostics for various health issues, streamlining the existing costly and lengthy processes of imaging and lab work.
Leadership Commitment
Under the stewardship of Chief Executive Officer Peter Whitehead, Light AI continues to commit to innovative solutions that prioritize health outcomes. The company is dedicated to enhancing healthcare accessibility through technology, proving that advanced diagnostics can reside in the palm of our hands.
Frequently Asked Questions
What is the recent announcement by Light AI?
Light AI has successfully closed its over-allotment option, raising an additional $1,516,350 through the purchase of more units.
When did trading on Cboe Canada start?
The trading of Light AI shares on Cboe Canada commenced on January 8, 2025.
What technology does Light AI develop?
Light AI develops AI-based health diagnostic applications for smartphones, focusing on quick disease identification.
How does Light AI's algorithm perform in diagnostics?
The algorithm has shown a 96.57% accuracy rate in diagnosing conditions like Group A Streptococcus.
What is the company's future vision?
Light AI aims to create a Digital Clinical Lab that integrates AI with smartphones to provide accessible health diagnostics for a range of conditions.
